Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 1;41(2):198-206.
doi: 10.3343/alm.2021.41.2.198.

Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma

Affiliations

Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma

Hyojin Chae et al. Ann Lab Med. .

Abstract

Background: Hepatocellular carcinoma (HCC) is the second-most-common cause of cancer-related deaths worldwide, and an accurate and non-invasive biomarker for the early detection and monitoring of HCC is required. We assessed pathogenic variants of HCC driver genes in cell-free DNA (cfDNA) from HCC patients who had not undergone systemic therapy.

Methods: Plasma cfDNA was collected from 20 HCC patients, and deep sequencing was performed using a customized cfDNA next-generation sequencing panel, targeting the major HCC driver genes (TP53, CTNNB1, TERT) that incorporates molecular barcoding.

Results: In 13/20 (65%) patients, we identified at least one pathogenic variant of two major HCC driver genes (TP53 and CTNNB1), including 16 variants of TP53 and nine variants of CTNNB1. The TP53 and CTNNB1 variants showed low allele frequencies, with median values of 0.17% (range: 0.06%-6.99%) and 0.07% (range: 0.05%-0.96%), respectively. However, the molecular coverage of variants was sufficient, with median values of 5,543 (range: 2,317-9,088) and 7,568 (range: 2,400-9,633) for TP53 and CTNNB1 variants, respectively.

Conclusions: Our targeted DNA sequencing successfully identified low-frequency pathogenic variants in the cfDNA from HCC patients by achieving high coverage of unique molecular families. Our results support the utility of cfDNA analysis to identify somatic gene variants in HCC patients.

Keywords: CTNNB1; Cell-free DNA; Hepatocellular carcinoma; Molecular barcoding; Next-generation sequencing; Pathogenic variants; TERT; TP53.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Mean observed molecular count (VAF) compared with the designed VAF of the reference material for the six variants. Abbreviation: VAF, variant allele frequency.
Fig. 2
Fig. 2
Passing–Bablok regression analysis plots for comparison of the observed and designed VAFs for each of the six variants are shown. The slope of the linear regression line for each variant ranged from 0.57 to 1.03, and, for TP53 p.R248Q and TP53 p.C242fs*5 variants, the 95% confidence interval (CI) of the slope contained 1.0. Abbreviation: VAF, variant allele frequency.

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Korean Liver Cancer Association and National Cancer Center, author. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019;13:227–99. doi: 10.5009/gnl19024. - DOI - PMC - PubMed
    1. Farokhizadeh Z, Dehbidi S, Geramizadeh B, Yaghobi R, Malekhosseini SA, Behmanesh M, et al. Association of microRNA polymorphisms with hepatocellular carcinoma in an Iranian population. Ann Lab Med. 2019;39:58–66. doi: 10.3343/alm.2019.39.1.58. - DOI - PMC - PubMed
    1. Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol. 2019;25:335–43. doi: 10.3350/cmh.2019.0010. - DOI - PMC - PubMed
    1. Yang K, Sung PS, You YK, Kim DG, Oh JS, Chun HJ, et al. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response. HPB (Oxford) 2019;21:1718–26. doi: 10.1016/j.hpb.2019.04.017. - DOI - PubMed